On November 4, 2025 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, reported that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) (Free SITC Whitepaper) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will take place at the SITC (Free SITC Whitepaper) Annual Meeting on Friday, November 7th from 8:30AM to 9:30AM in the National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
The presentation will also be live streamed: (View Source).
Speakers at the event will include:
· Dr. Dmitriy Zamarin of the Icahn Genomics Institute and the Precision Immunology Institute at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Zamarin is a world renowned expert in virotherapy. Dr. Zamarin is a member of Calidi’s Scientific Advisory Board (SAB).
· Dr. Antonio F. Santidrian, Chief Scientific Officer of Calidi, responsible for leading all of the Company’s research and development initiatives.
· Dr. John M. Wrangle, a thoracis medical oncologist at the Medical University of South Carolina (MUSC). Dr Wrangle is an expert on the clinical development of IL-15 superagonist. Dr. Wrangle is also a member of Calidi’s SAB.
· Dr. Travis Clifton, Chief Medical Officer of Calidi and a surgical oncologist with over 17 years of experience in drug development, early phase and translational clinical trials, and cancer immunotherapy.
"We are excited to hold our first investor event," said Eric Poma, PhD, Chief Executive Officer. "We believe CLD-401 and the RedTail platform represent important breakthroughs in the area of genetic medicine, and we look forward to updating the investment community on our progress."
Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by the end of 2026. The company is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
(Press release, Calidi Biotherapeutics, NOV 4, 2025, View Source [SID1234659347])